Trials / Completed
CompletedNCT00726323
A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)
A Phase II Study of the c-MET RTK Inhibitor XL880 in Subjects With Papillary Renal-Cell Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 74 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in papillary renal cell carcinoma. Papillary renal cell carcinoma may be classified into hereditary and sporadic forms; subjects with either classification will be accepted into this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | foretinib (formerly GSK1363089 or XL880) | treatment with oral foretinib on one of 2 dosing regimens: 240 mg on a 5 day on / 9 day off schedule every 14 days, or 80 mg on a daily dosing schedule |
Timeline
- Start date
- 2006-06-30
- Primary completion
- 2010-08-18
- Completion
- 2010-08-18
- First posted
- 2008-07-31
- Last updated
- 2017-12-11
- Results posted
- 2017-12-11
Locations
12 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00726323. Inclusion in this directory is not an endorsement.